Join or Renew Your Membership Join

Log In

Forgot Password?
Create New Account

Loading... please wait

2022 Annual Meeting Virtual Experience | C39 - Neurodegenerative Disorders (Spanish)

Tuesday 04/26/22
04:00 PM - 05:10 PM EDT Add To Calendar
This program will be presented both in-person and online
This program will be available in the meeting's On Demand product.
Seminar
Ildefonso Rodriguez-Leyva, MD, PhD, FAAN
Marta San Luciano, MD, FAAN
Aging, Dementia, and Behavioral Neurology
Population ageing in the XXI century became associated with a significant increase of neurodegenerative diseases. The most frequent is Alzheimer's disease (AD), where the progressive alterations on higher brain functions, including memory, language and spatiotemporal perception, are associated with misfolding, accumulation and spreading of amyloid peptide (Aβ) and Tau protein. For this reason, these protein deposits are the current therapeutic targets. Nevertheless, the strategy has been ineffective, and AD progression remains incurable. This seminar will detail the new AD paradigm, focused on neuronal identity loss and aberrant cell cycle reentry. This current AD approach centred on the neuronal nucleus is giving rise to new and completely different targets for intervention in AD, which will allow prevention and halt the progression of this devastating disease.
El envejecimiento de la población mundial en el siglo XXI se asocia a un aumento muy significativo de las enfermedades neurodegenerativas, siendo la más frecuente la enfermedad de Alzheimer (EA). Las alteraciones progresivas de funciones cerebrales superiores tales como la memoria y el lenguaje, así como de la percepción del espacio y del tiempo, se asocian a plegado defectuoso, almacenamiento y propagación de proteínas, especialmente de beta amiloide (Aβ) y Tau. Por esta razón, los blancos terapéuticos actuales son los acúmulos proteicos. Desafortunadamente, la estrategia no ha sido efectiva y la progresión de la EA sigue siendo incurable. En este seminario se detallará el nuevo paradigma de la EA, centrado en la pérdida de la identidad neuronal y la rentrada aberrante en el ciclo celular. El abordaje de la EA desde el núcleo neuronal está habilitando nuevos y totalmente diferentes blancos de intervención que prevendrán y detendrán la progresión de esta enfermedad devastadora.  
1.00 CME credit
Spanish Language

Program Materials Program Evaluations

Event Timeline
04:00 PM - 04:15 PM EDT Speaker Beta amiloide y Tau en el modelo clásico de AD
Ildefonso Rodriguez-Leyva, MD, PhD, FAAN
04:15 PM - 04:30 PM EDT Speaker Tau y el nuevo paradigma del origen nuclear de AD
Maria E. Jimenez-Capdeville, PhD
04:30 PM - 04:45 PM EDT Speaker La frontera entre el envejecimiento neuronal y la neurona AD: ciclo celular
Maria E. Jimenez-Capdeville, PhD
04:45 PM - 05:00 PM EDT Speaker Repercusiones clínicas
Ildefonso Rodriguez-Leyva, MD, PhD, FAAN
05:00 PM - 05:10 PM EDT Q&A Preguntas y respuestas
Ildefonso Rodriguez-Leyva, MD, PhD, FAAN, Maria E. Jimenez-Capdeville, PhD
Faculty Disclosures
Ildefonso Rodriguez-Leyva, MD, PhD, FAAN Dr. Rodriguez-Leyva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Rodriguez-Leyva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Laboratorios Carnot. Dr. Rodriguez-Leyva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Rodriguez-Leyva has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Lilly Eli and Company. Dr. Rodriguez-Leyva has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Torrent Pharmaceuticals Mexico. Dr. Rodriguez-Leyva has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for abbvie allergan.
Maria E. Jimenez-Capdeville, PhD No disclosure on file
Marta San Luciano, MD, FAAN Dr. San Luciano has received research support from NIH (NINDS).